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Abstract
Background: In Switzerland, research with identifiable human tissue samples, and/or its accompanying data, must
be approved by a research ethics committee (REC) before it can be allowed to take place. However, as the demand
for such tissue has rapidly increased in recent years, and biobanks have been created to meet these needs,
committees have had to deal with a growing number of such demands. Detailed instructions for evaluating every
kind of tissue request are scarce. Committees charged with evaluating research protocols therefore sometimes face
uncertainty in their decision-making.
Methods: We examine how a pool of Swiss REC members deal with a number of cases involving human
tissue, in order to determine the standards they adhere to, and their understanding and implementation of
existing laws and guidelines.
Results: There is considerable divergence in the approaches and decisions of Swiss REC members regarding
human tissue sample requests, particularly concerning the issue of informed consent. Despite recent trends
towards less strict consent requirements for biosample research, many of our respondents continue to employ
demanding standards for researchers. The question of informed consent, and the circumstances in which it is
required, continues to result in differences of opinion.
Conclusions: While room for local and cultural interpretation is essential to the workings of an REC,
misunderstanding of existing guidelines, or an absence of regulation in sensitive areas, will only lead to
suboptimal functioning of the REC itself. Our data suggests that there is uncertainty and disagreement on the
question of consent for human tissue sample, which existing laws and guidelines may not fully clarify.
Methods to address these uncertainties should be implemented in order to ensure efficient and harmonious
review of research protocols.
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Background
Research involving human tissue, with or without accom-
panying clinical data, is currently regulated in Switzerland
by a number of sources. The most specific is the Law on
Research on Human Subjects (Humanforschungsgesetz),
which addresses tissue samples in Articles 32 to 35 [1].
The Swiss Academy of Medical Sciences (SAMS) has de-
veloped a full set of guidelines outlining best practices for
biobanks, and these also offer some guidance on work
with tissue samples [2]. Elsewhere, the Federal Law on
Pharmaceuticals and Medical Products [3], and the vari-
ous cantonal laws, also apply to some aspects of biosam-
ple research.
While the SAMS and existing European guidelines [2, 4,
5] and domestic law provide some important information
for researchers, and the ethics committee members who
must regulate this research, the rapidly evolving nature of
the field, coupled with the increase in demand for tissue
samples, means that there are still unclear issues arising [6].
How exactly should the degree of anonymisation of the
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samples affect the ethical review process [7]? What sort of
consent form must be obtained for human tissue samples
[8–13]? Should results be returned to donors, particularly if
a potentially dangerous diagnosis is uncovered [14]? These
matters are still widely debated in the literature, yet they
are crucial for research ethics committees (RECs) in their
assessment of research protocols.
Studies assessing the decision criteria of RECs are scarce
[15] and do not specifically address research involving bio-
logical samples. Our study is an initial assessment of the
approaches of Swiss REC members to research protocols
involving informed consent to human tissue sample use.
Informed consent refers to the consent form which all
Swiss ethics committees require for prospective studies.
This is, except in exceptional cases, provided in written
form. In the case of retrospective studies, the SAMS re-
quires consent for the use of samples which are not fully
anonymized. These requirements are identical for all com-
mittees in Switzerland. 7 RECs are responsible for all 26
cantons, and meet on a fortnightly basis (typically) to
make decisions on applications for research projects in-
volving human subjects or material. Committees are made
up of a number of experts, with backgrounds ranging
from medicine, to law, to nursing, to psychology, although
for each application, only a small number of experts from
this pool will be involved.
The aim is to understand how the committees and their
members respond to such requests, whether responses
differ between committees and their members, and some
of the reasons for their approval or rejection of various
parts of the study protocol. By understanding the ways in
which decisions are made, and what areas produce uncer-
tainty, it is possible to uncover issues which may require
more discussion and clarification for REC members and
researchers. The aim of our study was not to obtain statis-
tically representative results, but to explore broadly which
issues are the most controversial and why. We therefore
adopted a qualitative approach, asking participants to pro-
vide comments, in order to understand the reasoning be-
hind the decisions of the committee members. The study
is also a didactic means to encourage further discussion of
the addressed issues.
Methods
After discussions with a number of Swiss ethical and
legal experts and researchers involved in biobanking, a
questionnaire was created based upon three fictional
case examples, with several subsequent questions.
These examples were designed specifically for the study
to address various aspects of the informed consent
process that were of particular interest to the re-
searchers. These case examples, and the questionnaires
which follow them, have not been validated. In
Switzerland, research which is anonymised and not
related to health or medical issues does not require eth-
ical review [1]; consequently, no ethical review process
was undertaken for this study.
The first case was followed by six closed and four open
questions, the second by eight closed and six open ques-
tions, and the third by nine closed and eight open ques-
tions (see Additional file 1 for all questions.) Responses
were given using a 5-point Likert-type scale (certainly
agree, probably agree etc. to certainly disagree) [16], and
we asked participants to provide comments after each
question explaining the reasons for their responses.
Agreement was categorized as a response of either “cer-
tainly” or “absolutely”, while disagreement was defined
as a response of “probably not” or “certainly not”. Re-
sponses of “I don’t know” were not categorised as posi-
tive or negative, but counted separately. The aim was to
support quantitative findings with qualitative data on the
reasons for respondents’ decisions. This was felt to be an
essential part of this study, as clarity about the reasons
for possible misunderstandings or divergent answers are
necessary for the improvement of future laws and guide-
lines. The case studies were designed to prompt re-
sponses on the committees’ approach to proposed
research using human data and tissue.
Committees were identified via online searches for
RECs in Switzerland. The presidents of these commit-
tees were contacted via email, provided with informa-
tion about the nature of the study, and invited to
take part. Committee presidents who agreed to do so
received an information sheet about the study, outlin-
ing the requirements and aims, which they distributed
to all individual members. Questionnaires were sent
to the presidents of all working RECs in the French
speaking parts of Switzerland While the cantons of
Valais and Vaud have one cantonal commission with
or without subsections, Geneva was at the time of
the study composed of 4 research ethics (sub)commit-
tees supervised by one central commission at the
University Hospitals of Geneva, and we included all 4
subcommittees. At the time of the study, the joint
commission of the cantons Neuchatel, Fribourg and
Jura was under reconstruction and not available and
was therefore not included. One phone call and one
follow up email were used as reminders.
Three case study questions were used to introduce
the issues to participants. The first concerns [1] a re-
quest for tissue sample without accompanying data.
The second [2] concerns a request for tissue with ac-
companying data. The third [3] deals with the drafting
of a biobank’s written consent form. Questionnaires
were completed either on paper and returned by post,
or scanned and returned via email. Participants were
informed that they were under no obligation to
complete the questionnaire, and that the data would be
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anonymized; completing the questionnaire was taken as
consent to participate. Upon receipt of all completed
questionnaires, the primary investigator entered all data
into a coded spreadsheet, with a single hard copy of the
code key maintained in the possession of another inves-
tigator. Completed questionnaires were analysed by all
authors. Responses to closed questions were grouped
according to Likert scale levels. For open questions,
two researchers independently analysed all responses
and grouped them into categories based on theme and
the nature of response (in many cases, for example,
whether the response was positive or negative). Both
researchers then compared findings and, in case of dis-
agreement, asked a third member of the study team to
resolve the issue.
Results
Overall, we received a total of 31 completed questionnaires:
22 members of committees from Geneva, 6 from Vaud,
and 2 from Valais responded. One commission president
opted to discuss the questionnaire during a committee
meeting and to provide one single response for the entire
REC, while in the other committees, participants answered
the questionnaire individually and anonymously. Conse-
quently, the collective answer of this committee are
counted as one response, as only one questionnaire was
returned. This means that differences of opinion among the
members of this committee cannot be determined; the data
from this group response are valuable in light of the com-
parison between committees within the French-speaking
part of Switzerland. Intra-committee disagreement is
reflected by other committees.
We include some totals representing the results of
the Likert scale questions not to make representative
quantitative conclusions, but in order to indicate
which issues where particularly controversial among
respondents. In what follows, we present these re-
sults in particular to discuss the corresponding com-
mentaries that elucidate reasons explaining the
controversies.
Case 1: Must a request for tissue for research purposes
without accompanying data be approved by the entire
REC? (see Additional file 1: Case 1)
The majority of respondents (25 out of 31) replied that, ac-
cording to the recommendations followed by their commit-
tee, such a request would need to be approved by the
committee as a whole, not fast-tracked (i.e. decided by the
president only).
With regards to the open questions, respondents men-
tioned that the president alone was not the appropriate
judge of such requests, and that the study protocol still
had to be carefully verified.
Would you approve the project if the sample were
irreversibly anonymised?
A total of 21 out of 31 participants responded in favor of
this proposition, with only four strongly opposing it. Re-
spondents were also asked whether the patient’s consent
would be required in such a case. Twelve respondents
stated that consent would be necessary, 16 that it would
not be necessary, while the rest were undecided.
From the qualitative questions, of those who felt that
consent was not necessary, the decisive factor was the lack
of risk to the patient: “No risk of misuse”; “No benefit or
risk to donor”; “Unnecessary and costly administrative
procedure”. Those who said that consent ought to be ob-
tained felt that “regardless of study type, the patient must
be informed”, and that “a biopsy is the patient’s property”.
Would you approve the project if the samples were
reversibly anonymised (i.e. identifiable via a code)?
Elaborating on the previous question, participants were
asked whether the degree of anonymisation was the de-
cisive factor in their approval of a project. In this case,
22 out of 31 respondents wrote they would still approve
the project, although notably, more chose the “probably”
option than in the previous question.
Case 2: Must a request for tissue for research purposes
with accompanying data be approved by the entire REC?
There was virtual unanimity (29 out of 31 in favour) on the
fact that such samples, regardless of the degree of anonymi-
sation, must be approved for use by the entire committee.
Is the consent of the donor necessary for such a tissue
request?
A total of 18 respondents stated that consent was required
if the tissue was irreversibly anonymised, and 11 felt that
it was, at least probably, not necessary. For the use of
identifiable samples, 27 said consent would be required,
with only two stating that it might not be necessary.
When asked to explain their views on both cases in
the open questions, most held that consent was an auto-
matic requirement for sample use. One participant
stated: “Quality and results depend on the cooperation
of the donor, which is only possible if he has consented”,
while another wrote “If the samples are not irreversibly
anonymised, the patient must be asked if he wishes to
receive results, and potentially, bad news.” However, an-
other respondent felt that “There are situations in which
it is preferable that the patient not be contacted.”
Should the discovery of a potentially bad health outcome
be shared with the donor?
A total of 23 respondents thought that at least probably,
such a discovery should be shared with the donor. Four
disagreed, and four were unsure.
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Based on the qualitative data, it appears that many of
those who felt that the information should be shared
commented on the fact that this must be made clear,
and established, at the time of obtaining consent. Those
who felt that perhaps the patient should not be con-
tacted cited the possible unreliability of the study, and
indeed the patient’s desire. The respondent had appar-
ently assumed that the patient was aware of this possi-
bility, and therefore agreed, in principle, that results
should generally be returned.
Case 3: Do RECs find a multiple choice consent form
acceptable?
A total of 12 out of 31 respondents reported that
they were probably or certainly opposed to a multiple
choice consent form (see Additional file 1: case 3,
highlighted in the box), while 15 would at least prob-
ably accept it. An examination of the data reveals that
in two separate cases, members of the same REC held
diametrically opposing views.
Should the choice permitting the samples to be used in
any future medical research appear on the form (blanket
consent)?
An almost even split was found for responses to this
question, with 14 respondents opposing the suggestion,
16 in favour, and one unsure.
When explaining their responses, respondents who
opposed this formulation of a blanket consent felt that
the patient would not be sufficiently informed to make a
proper decision. Interestingly, they indicated that a blan-
ket consent was practically impossible, not simply un-
desirable. Among the comments on this proposal were:
“Too vague”, “Insufficient information for the patient”,
“Prior consent would be required”, and “The protocol
must describe the specific goals of the research”. One re-
spondent cited the SAMS guidelines on biobanking stat-
ing that Article 4.3 of the guidelines does not permit
blanket consent (however the respondent apparently had
a different understanding of the guidelines, as in fact,
the article does allow for a “general” form of consent
encompassing unspecified future uses).
Of those in favor of blanket consent, only one re-
spondent gave a reason: “Patients in a hospital must ex-
pect their samples to be used in future research unless
they sign a form refusing this.” On this point, in three
separate cases members of the same committee gave di-
verging responses.
Should the choice permitting the samples to be used for
research on colorectal cancer appear on the form?
Four respondents opposed this suggestion, will two were
undecided.
Based on the qualitative data, respondents in favor of
this proposition approved of the fact that it limited the
scope of the research to a specific domain, and that it
was explicit enough to ensure that the donor would
know what he was agreeing to. One respondent ex-
plained “It seems sensible to me that if one goes to the
trouble of creating a biobank, one ought to be able to
use the samples for any aspect of colorectal cancer re-
search, with the proper REC approval.”
Those who opposed this choice stated, once more, that
it was too broad. One respondent felt that it would be
sufficient to indicate that the intended research was in
the field of genetics. Others felt that this option was still
too vague to enable the donor to be properly informed
in his consent, though this option seemed to be gener-
ally more acceptable than the previous one..
Should the choice permitting the samples to be used for
research on the APC gene appear on the form?
Again, four respondents opposed this suggestion, with
two undecided, leaving twenty-five in favour. As justifi-
cation for these choices, certain respondents reported
that this choice was “vague”, with one stating that “One
must always specify the exact details of the research pro-
ject,” and another stating that even research on a spe-
cific gene might have many aspects which the donor
would not be aware of.
Others felt that this provision was unduly limiting, as
“it would require the researcher to re-contact his pa-
tients if he wished to perform further research” and “it’s
restrictive: one could discover useful things on colon
cancer.” One committee showed that two members held
opposing views on this topic.
Discussion
Discussions about criteria for ethics approval of research
involving tissue samples have been a feature of literature
in a theoretical form for some time. The uniqueness of
our study is that we have used detailed case examples
and solicited the opinions of REC members about
whether and under which conditions the projects should
be approved. This debate can only be meaningfully ad-
vanced if the discussion takes into account real-world
situations, and includes the actors directly involved in
the decision making.
For these reasons, a particularly important finding of
our study is that there is considerable divergence in the
approaches and decisions of Swiss REC members regard-
ing human tissue sample requests. In some cases, only a
few members of certain committees express different
viewpoints, or raise questions concerning the examples
used. However, on a number of issues, there are significant
differences in approach. Some differences may be due to
cantonal or institutional regulations; while all committees
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in Switzerland must ensure that the same national and
international laws are upheld, many research applications
come from universities. These frequently differ with
regards to data storage and sharing policies, and may face
logistical challenges, such as lack of sample storage space
or cooperation with international partners, which present
challenging situations for the relevant RECs. More import-
antly, our results also demonstrate that members of the
same cantonal committee hold opposite views. Divergence
might be caused by a lack of knowledge, understanding,
or clarity of laws and guidelines and would point to a need
for more specific training and clarification from the
inter-cantonal REC association (AGEK, Swissethics).
These being the areas which can and must be improved
on in order to allow optimal REC functioning, it is essen-
tial to understand their extent. Inconsistency and
disagreement in RECs, both internal and between inde-
pendent committees, can slow research, and can result in
varying interpretations of laws and regulations which dir-
ectly affect research participants [17, 18]. Our findings are
an initial indication of areas which require some
harmonization efforts.
The most notable finding of our study is that all three
case examples, the greatest areas of disagreement con-
cerned informed consent. Below, we discuss the points
which produced significant differences, and suggest ways
in which this could be minimized.
Questions related to case 1 revealed that a high level
of disagreement existed between committee members on
whether research involving irreversibly anonymised sam-
ples, with no accompanying clinical data, would require
the informed consent of the donor. The SAMS guide-
lines [2] state, in section 4.3, that no express consent is
required for such research. Irreversibly anonymised sam-
ples are widely held to pose virtually no risk to donors
when used in research, and it is frequently argued that
this lessens the need to obtain fully informed consent
[19, 20]. Hence, requests for consent by RECs risk slow-
ing the progress of research [12, 21]. It may be that re-
spondents who stated that they would refuse such
requests are not frequently confronted by requests per-
taining to tissue samples, and apply the criteria that gov-
erns research on humans subjects.
While at the time of the survey the Law on Human
Subject Research was not in effect, it is worth noting
that its current wording may still be perceived as am-
biguous by those tasked with upholding it. Informed
consent is not required if obtaining it would be impos-
sible or very difficult, or if the ends of the research out-
weigh the interests of the donor; it may be the case that
specific, case-based examples would facilitate the
decision-making process for REC members who are
tasked with finding the appropriate balance between re-
search and patients interests. Furthermore, the SAMS
guidelines emphasise that inappropriate irreversible
anonymisation should be avoided: “Both in the interests
of the patients and in the interests of research, samples
and data should not be irreversibly anonymised, as far as
this is possible. For the patient, irreversible anonymisa-
tion means that generally he can no longer be informed
of relevant results; for research, it means that the sam-
ples and the data lose in informative value” [2](p.6).
Regarding case 2, the most noteworthy result is that
almost two-thirds of respondents are convinced that
consent is necessary for samples accompanied by clinical
data, regardless of whether or not they were irreversibly
anonymised. When comparing case 1 to case 2 it seems
that the existence of accompanying clinical data is a mo-
tivating factor in the need for obtaining consent.
Whether committee members feel that this increases the
risk (which will depend on the richness of the data and
the procedure of anonymisation), or that it increases the
chance that useful results are found (a realistic possibil-
ity, given the views on return of results) is not clear. As
noted above, the SAMS guidelines, and the Declaration
of Helsinki [22], do not make such a requirement. The
Law on Human Research now makes clear that this is
not always the case, which may contribute to resolving
disagreement on this point.
Case 3 gives some of the most detailed explanation
of respondents’ decision making, and provides insight
into Swiss committee members’ approaches to the
divisive field of consent in biobanking. Informed con-
sent procedures typically receive a great deal of focus
in ethics review [23]. In Switzerland, informed con-
sent is protected, though not explicitly, by Article 10
of the Swiss constitution [24] and Article 28 of the
Civil Code [25]. As well as being a crucial aspect of
every international declaration on health care ethics
since the Nuremberg Code, it is defended by Article
1 of the SAMS manual on research on human sub-
jects [26]. Switzerland therefore operates under a legal
and ethical framework which recognizes the primacy
of informed consent in medical research.
Of the individual consent options (which could, but
must not necessarily, form part of a multiple choice
form), a majority of respondents opposed the notion of a
blanket consent. An even greater majority, however,
were in favor of the two more specific options for con-
sent. The more restrictive option (APC gene research)
was no more favored than the slightly broader one (colo-
rectal cancer research). Interestingly, those respondents
who would accept a multiple choice form would in most
cases also accept a more broad consent. These options
represent a somewhat enlarged approach to consent in
comparison to the traditional human subject require-
ments, so the correlative acceptance of both ideas is per-
haps to be expected.
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Our results show that only about half of the respon-
dents approve of these more open approaches to con-
sent, demonstrating that this remains controversial
among the participating REC members. According to
the Law on Human Subject Research, biological material
may be reused in coded or non-coded form if the sample
source has consented after having received sufficient in-
formation. The exact definition of how general or de-
tailed the information may be in order to be considered
sufficient will remain at the discretion of individual
RECs. This is likely to be a key factor in the disagree-
ments reported, as it represents an issue free of strict
regulation, in which the experiences and perhaps the
local context of committee members (such as the re-
search focus on the universities they represent) take on a
prominent role in decision making. It may, however, still
be desirable for RECs to work towards harmonization
on this matter, as any study which requires a
multi-centric project to be approved by various commit-
tees risks confusion and potentially a stalled or blocked
application.
Our results indicate that at present REC members pre-
fer to err on the side of restriction as many respondents
have chosen to adhere to the traditional form of consent
used in clinical trials. However, there seems to be grow-
ing agreement that the specifics of the study protocol
can affect the level of consent and the details of informa-
tion deemed necessary. Clearly, the interpretation of the
SAMS guidelines and the Law on Human Research
should be clarified in further training for REC members.
Indeed, the guidelines do not prohibit blanket consent,
as one respondent claimed, but might require more spe-
cific consent, if the primary investigator is aware of his
planned research and reuse of the samples before he
takes the samples. Here again, if the sample is part of a
tissue extraction undertaken for treatment purposes, the
need for specific consent may not arise (for a full discus-
sion of the intricacies and different scenarios which can
occur, see Junod and Elger, (2010) [1]).
Finally, it should be noted that in case 3, on a number
of occasions, members of a single ethics committee give
different responses as to how their committee operates.
This represents a noteworthy lack of agreement about the
very policies and practices of the committee. If not all
members of one committee agree about how protocol re-
view should be handled, transparent criteria need to be
used to resolve the inconsistencies. Our study highlights
the need for committees to work closely, and together
with committees from other cantons, in order to ensure a
well-argued and transparent level of ethical review.
Disagreement between REC members and different
RECs [15] occurs for three main reasons. Different com-
mittees may assess risks and benefits using particular par-
adigms, or may assign different worth to certain values,
for example patient autonomy versus public good [23].
This is an integral part of the ethical review process itself,
allowing for consideration of local norms and standards,
and detailed analysis of the need for research in that par-
ticular time and place. However, as addressed above, dis-
agreement can also be caused by a lack of knowledge or a
variable interpretation of relevant laws and guidelines (or
indeed, the details of the protocol), or by an absence of
such documents. In all of these cases, decisions appear to
be influenced factors which have no solid basis in current
law, hence differences of this kind should be minimized as
far as possible. However, it is important to bear in mind
that guidelines and laws as well as their interpretation
may change over time, and are also sometimes left deliber-
ately vague. Legislators may have purposely left certain
parts of the law open to interpretation to allow for a de-
gree of variation and adaptation to local culture or cir-
cumstances. The lack of specificity may, however, have the
secondary effect of leaving committee members with in-
sufficient guidance [15].
Our results indicate that there are some differences in
the decisions made by Swiss ethics committees which can-
not be explained simply by regional differences. Particu-
larly important are the approaches to requiring informed
consent for unidentifiable samples, and the various views
on the level of consent necessary when tissue samples are
obtained. We have suggested that this may be a result of
the fact that traditional paradigms of informed consent
are giving way to more relaxed recommendations in the
case of tissue samples, and that certain ethics committees
have yet to “catch up” with these changes.
It is essential that ethics committees in Switzerland are
fully aware of the laws which will affect their assessment
of study protocols, and that all members of the commit-
tee are kept up to date with new developments. A
Switzerland-wide training and information programme
for committee members would be one way of working
towards this [27]. Consultation with committees on the
optimum way to transmit such information would also
be a useful step. It has also been suggested that ethics
committees could create sub-groups with specialisms in
certain types of study [15].
Limitations
Our study has several limitations. We have included only
RECs from one language region in Switzerland; hence,
this study is not representative of all of Switzerland, but
merely serves an example of some of the issues encoun-
tered one part of country. Due to the higher number of
REC members in the subcommittees in Geneva, the
opinions of REC members in this canton are overrepre-
sented. On the other hand, this represents to some ex-
tent the charge of protocols: RECs in cantons with
university hospitals treat a much higher number of
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protocols than RECs in cantons without a university
hospital. Furthermore, our aim has not been to present a
quantitative overview about opinions in Switzerland but
to explore agreement and disagreement among REC
members of the same committees and across some other
cantons. The research design, including the qualitative
analysis of the comments, has enabled us to show sig-
nificant controversy. However, the present data does not
allow for any understanding of the reasons for disagree-
ment or difference in interpretation between committee
and their members, and we recommend this as a topic
for future studies. Another limitation is the hypothetical
nature of the cases. We did not evaluate how RECs
would react to real protocols and answers could be in-
fluenced by social desirability. However, we ensured
strict anonymity of the answers, and given their some-
times controversial tone, we have no indication for a
one-sided social desirability bias.
Conclusion
As samples of human biological material become in-
creasingly widely used in research, the traditionally
strict requirements for informed consent are becoming
more flexible, reflecting the potential benefits of such
research, and the minimization of physical risk to hu-
man donors. Switzerland’s Law on Human Subject Re-
search and changes to the Helsinki Declaration [28]
reflects this trend. At present, there is a division in
Swiss ethics committees on a number of issues con-
cerning the use of human biosamples. While this div-
ision perhaps is to be expected at a time when
regulations are changing, differing standards within
RECs and between cantons are undesirable. They may
be confusing to researchers, hamper prospective stud-
ies, and even contravene accepted guidelines. In
addition, certain cantons may develop a reputation as
being “easy to please”, while others will be avoided for
their strict regulations, with potentially disruptive ef-
fects in scientific research in Switzerland. Our results
show that discrepancies do exist across all participants,
i.e. between cantons as well as within committees. Edu-
cation and further training of researchers and commit-
tee members on ethical and legal issues surrounding
research involving biobanks would be helpful to clarify
uncertainties and to support timely and harmonized re-
search review. For example, a half-day course summar-
izing relevant legal requirements and standards put in
place by international guidelines, similar to good clin-
ical practice training, could contribute towards more
clearly informed decision-making. A monthly handout,
produced by the SAMS and summarizing new develop-
ments or frequently asked questions, could also be a
valuable and not excessively demanding way of keeping
committee members informed.
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